People
Tolion Board of Directors
Board of Directors
Martin Tolar, MD, PhD
Founder & Executive Chairman
Founder, President & CEO, Alzheon, Inc.
Martin Tolar, MD, PhD
Dr. Tolar serves as the Founder, President & CEO of Alzheon. Prior to founding Alzheon in June 2013, Dr. Tolar held executive positions in several life sciences companies, where he has successfully established and grew new companies, business areas and product opportunities. Dr. Tolar served as President & CEO of Knome, Inc., where he led the development of human genome interpretation systems and services for academic, pharmaceutical and clinical clients, as President & CEO at NormOxys, Inc., where he built the business for novel cancer and cardiovascular therapeutics, and as Chief Scientific Officer and Chief Business Officer at CoMentis, Inc., where he developed the first clinical-stage beta secretase inhibitor platform for Alzheimer’s disease and negotiated a collaboration with a potential value of more than $1.1 billion with Astellas Pharma in 2008. Dr. Tolar held a variety of clinical development and business leadership positions at Pfizer, where he was instrumental in a wide range of business transactions, including the acquisition of Rinat Neuroscience for $500 million in 2006, and directed programs through all stages of clinical development and FDA approval including NDA filings.
During his academic career, Dr. Tolar served as an Assistant Professor in the Department of Neurology at Yale University School of Medicine, where he focused on movement disorders. Dr. Tolar trained in Neurology at the Boston Medical Center, received a Ph.D. in Neuroscience for his work on the role of apolipoprotein E in pathogenesis of Alzheimer’s disease, and published many scientific publications in the areas of neuroscience and neurodegenerative disorders. Dr. Tolar received his M.D. from Charles University in Prague, where, as a medical student, he helped organize and lead the Velvet Revolution that toppled the communist regime in the former Czechoslovakia in November 1989.
In 2023, Dr. Tolar founded Tolion Health, Inc., to provide actionable, AI-powered brain health guidance with the objective of enhancing longevity, cognitive performance, and quality of life through science-backed interventions. The mission of Tolion extends beyond treatment to prevention and prediction of risk with the goal to transform the landscape of brain health by delivering targeted, individualized care and a future free from the burden of dementia. He serves as the Director of Tolion Board of Directors.
In 2021, Dr. Tolar founded the International Neurodegenerative Disorders Research Center, INDRC, a global institute applying artificial intelligence and machine learning solutions to identify and validate therapeutic interventions for Alzheimer’s disease and other neurodegenerative disorders. Dr. Tolar also serves on business and scientific boards including the Alzheimer’s Drug Discovery Foundation, the Alzheimer Foundation, the CERGE-EI Foundation, and Advance Healthcare Management Institute.
In 2024, Dr. Tolar received the Eliška and Zdeněk Strmiska Award from the Alzheimer’s Foundation for significant contribution towards the research and treatment of Alzheimer´s disease and donated the cash prize to the INDRC institute. In 2021, Dr. Tolar received the Czech Laurels Award from the Czech Chamber of Commerce in recognition of his leadership in Alzheimer disease therapeutics, as well as clinical, scientific, and business projects in the Czech Republic. The Czech Chamber of Commerce is the largest and the most representative business association in the Czech Republic. Dr. Tolar was recognized as one of the Top 100 Most Influential People in the world of drug development and manufacture by The Medicine Maker Magazine’s Power Lists for 2016, 2017, 2018 and 2019. Dr. Tolar was recognized as one of the CEOs to Watch in 2025 by the Fortune magazine.
Ken Mace, MBA
Director
Chief Financial Officer, Alzheon, Inc.
Kenneth Mace, MBA
Mr. Ken Mace brings to Alzheon more than 20 years of senior finance and operations leadership in leading, building and advising biopharmaceutical companies; with extensive experience with developing business plans, financing strategies and financial modeling. Previously, Mr. Mace served as the Vice President of Finance, New Ventures at Flagship Pioneering, a venture capital firm that creates and grows first-in-category life science companies, where he supported 20+ new venture entities. Before Flagship Pioneering, Mr. Mace was Vice Director and Senior Project Manager, Group Planning and Special Projects, with F. Hoffman-La Roche Ltd., where he provided financial analysis in support of long-range business planning. Earlier, Mr. Mace was Vice President of Finance and Global Operations at mtm laboratories AG, an in-vitro diagnostics company. In this role, he was responsible for finance and sales operations and was the finance lead for the $230 million acquisition by Roche Diagnostics. Mr. Mace also held positions of increasing responsibility with life science companies ViaCell, Inc., Cytyc Corporation and Boston Scientific Corporation.
Mr. Mace earned his MBA from Babson College and BS in Accounting and Finance from Roger Williams University.
Ing. Jaroslav Lískovec
Director
Head of Investor Relations, Tolion Health AI
Ing. Jaroslav Lískovec
Jaroslav Lískovec brings 15+ years of leadership experience. His background is primarily entrepreneurship in the technology sector. He has also implemented strategic projects for the government of the Czech Republic such as the creation of the largest strategic industrial zone Triangle, the establishment of a new state-owned enterprise NAKIT focused on technologies for eGovernment and critical communication infrastructure of the state.
He also created the National Centre for Industry 4.0 and was an advisor to the Minister of Industry and Trade on technology, innovation and economic strategy. In the area of startups, he is responsible for the commercialisation and technology transfer of research at CTU – the oldest technical university in Europe – and is co-founder of CTU’s first employee spin-off TRIX Connections.
Gregory J. Moore, MD, PhD
Director
Senior Advisor, Gates Ventures
Gregory J. Moore, MD, PhD
Dr. Gregory J. Moore is a physician, engineer, and technology executive with nearly two decades of leadership at the intersection of healthcare, artificial intelligence, and cloud technology. He most recently served as Corporate Vice President of Microsoft Health & Life Sciences (2019–2023), where he led global R&D strategy, engineering, and product development, including oversight of the $19.7B Nuance integration. Prior to that, he was Vice President and Founder of Google Cloud Healthcare & Life Sciences (2016–2019), where he launched and scaled Google’s global health vertical.
He is currently a Senior Advisor at Gates Ventures, focusing on health and life sciences, particularly in Alzheimer’s disease, imaging, AI, and global health research. He also serves as an Associate Fellow at Stanford University’s Center for Artificial Intelligence in Medicine and Imaging. Dr. Moore is on the boards of several organizations including DaVita, Cellarity, and Fortive, and has held academic appointments at Stanford, Penn State, and Wayne State University.
Jan Svoboda, MBA, MSc
Director
Co-Founder: VERTEX Group, Prime Fund, LongRiver Fund
Jan Svoboda
Jan Svoboda specializes in strategic management and acquisitions. He has been active in the market of Venture Capital investments and Private Equity for more than 15 years. His passion is modern technology, which is why he founded the technology fund Prime Fund, which covers these activities of his. At the same time, he founded Vertex Fund (a real estate fund and developer), where he is dedicated to the development of activities in the field of Real Estate development. He also has valuable know-how in the field of marketing and communication. In the past, he was a member of the supervisory board of AVANT investment company, a.s., the largest domestic manager of qualified investors’ funds. Even before he fully immersed himself in the world of investments, he worked in the position of marketing director of TV Prima and later as sales and marketing director of Czech Television.